<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03180710</url>
  </required_header>
  <id_info>
    <org_study_id>BC3-CT025</org_study_id>
    <nct_id>NCT03180710</nct_id>
  </id_info>
  <brief_title>A Trial to Investigate the Dose-linearity of BioChaperone® Combo 75/25 and the Safety at Three Different Doses in Subjects With Type 2 Diabetes</brief_title>
  <official_title>A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-linearity of BioChaperone® Combo 75/25 and the Safety at Three Different Doses in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adocia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adocia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a bicentric, double-blinded, randomised, four-period crossover phase 1 trial, using
      automated 30-hour euglycemic clamp in subjects with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a bicentric, double-blinded, randomised, four-period crossover phase 1 trial, using
      automated 30-hour euglycemic clamp in subjects with type 2 diabetes mellitus.

      Each subject will be randomly allocated to a sequence of four treatments, three single doses
      of BioChaperone® Combo 75/25 (0.6 U/kg, 0.8 U/kg or 1.0 U/kg) and one single dose of Humalog®
      Mix25 at 0.8 U/kg on four separate dosing visits.

      Subjects will come in a fasted state to the clinical trial centre in the morning of each
      dosing day and stay at the clinical trial centre until the 30-hour clamp procedures have been
      terminated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 6, 2017</start_date>
  <completion_date type="Actual">December 21, 2017</completion_date>
  <primary_completion_date type="Actual">August 28, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC last_total</measure>
    <time_frame>From 0 to 30 hours</time_frame>
    <description>Area under the plasma insulin concentration-time curve from t=0 to the last measured total insulin plasma concentration above LLOQ. The total insulin concentration is the sum of lispro and basal concentrations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax_total</measure>
    <time_frame>From 0 to 30 hours</time_frame>
    <description>Maximum observed plasma insulin total concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCGIR 0-last (mg/kg)</measure>
    <time_frame>From 0 to 30 hours</time_frame>
    <description>Area under the glucose infusion rate curve from 0 hours until the end of clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GIRmax (mg/kg/min)</measure>
    <time_frame>From 0 to 30 hours</time_frame>
    <description>Maximum glucose infusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tGIRmax</measure>
    <time_frame>From 0 to 30 hours</time_frame>
    <description>Time to maximum glucose infusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 102 days (maximum duration of subject's participation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local tolerability: number of injection site reaction</measure>
    <time_frame>Up to 102 days (maximum duration of subject's participation)</time_frame>
    <description>Frequency of injection site reaction in each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hypoglycaemic events in each treatment arm</measure>
    <time_frame>Up to 102 days (maximum duration of subject's participation)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>BioChaperone® Combo 75/25 at 0.6 U/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous injection of 0.6 U/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BioChaperone® Combo 75/25 at 0.8 U/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous dose of 0.8 U/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BioChaperone® Combo 75/25 at 1.0 U/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous dose of 1.0 U/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humalog® Mix25 at 0.8 U/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single subcutaneous dose of 0.8 U/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BioChaperone® Combo 75/25 at 0.6 U/kg</intervention_name>
    <description>Injection of BioChaperone® Combo 75/25 at 0.6 U/kg</description>
    <arm_group_label>BioChaperone® Combo 75/25 at 0.6 U/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BioChaperone® Combo 75/25 at 0.8 U/kg</intervention_name>
    <description>Injection of BioChaperone® Combo 75/25 at 0.8 U/kg</description>
    <arm_group_label>BioChaperone® Combo 75/25 at 0.8 U/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BioChaperone® Combo 75/25 at 1.0 U/kg</intervention_name>
    <description>Injection of BioChaperone® Combo 75/25 at 1.0 U/kg</description>
    <arm_group_label>BioChaperone® Combo 75/25 at 1.0 U/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humalog® Mix25 at 0.8 U/kg</intervention_name>
    <description>Injection of Humalog® Mix25 at 0.8 U/kg</description>
    <arm_group_label>Humalog® Mix25 at 0.8 U/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subject aged 18-70 years (both inclusive)

          -  Type 2 diabetes mellitus (as diagnosed clinically) for ≥ 12 months

          -  HbA1c level between 6.5% and 9.0 % (both inclusive)

          -  Body mass index between 20.0 and 40.0 kg/m2 (both inclusive)

          -  Body weight &lt;= 125.0 kg at the screening visit

          -  Insulin-treated subjects. Total insulin dose of &lt;= 1.2 (I)U/kg/day

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  Known or suspected hypersensitivity to IMP(s) or related products

          -  Previous participation in this trial. Participation is defined as randomised.

          -  Receipt of any medicinal product in clinical development within 60 days before
             randomisation in this trial.

          -  Clinically significant abnormal values for haematology, biochemistry, coagulation, or
             urinalysis as judged by the Investigator considering the underlying disease.

          -  Supine blood pressure at screening (after resting for at least 5 min in supine
             position) outside the range of 90-160 mmHg systolically or 50-95 mmHg diastolically
             (excluding white-coat hypertension; therefore, if a repeated measurement shows values
             within the range, the subject can be included in the trial); symptoms of arterial
             hypotension and/or a heart rate at rest outside the range of 50-90 beats per minute.
             This exclusion criterion also pertains to subjects being on anti-hypertensives.

          -  Women of child bearing potential not willing to use contraceptive methods.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver Klein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institut für Stoffwechselforschung GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Mainz GmbH &amp; Co. KG</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2017</study_first_submitted>
  <study_first_submitted_qc>June 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2017</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Lispro</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

